|
|
|
Effective Date: 04/01/2012 |
Title: Dorsal Column Stimulator for Pain
|
Revision Date: 07/01/2020
|
Document: BI348:00
|
CPT Code(s): 63650, 63655, 63685, 63688, A4290, C1767, C1816, C1820, E0745, L8680-L8689
|
Public Statement
|
Effective Date:
a)
This policy
will apply to all services performed on or after the above revision date which
will become the new effective date.
b)
For all
services referred to in this policy that were performed before the revision
date, contact customer service for the rules that would apply.
1)
Spinal cord
stimulation (dorsal column) requires pre-authorization.
2)
Spinal cord
stimulation is used to treat severe pain in the limbs and back that has not
responded to all other forms of therapy.
|
Medical Statement
|
1.
Dorsal column stimulators
(DCS) are covered with preauthorization
for the management of members with chronic pain that has not responded to all
other forms of therapy*** and is due to:
a)
Failed back surgery
syndrome with low back pain and significant radicular pain
(M96.1), or
b)
Complex regional pain
syndrome (also known as reflex sympathetic dystrophy),
(G90.50 – G90.59), or
c)
Inoperable chronic
ischemic limb pain secondary to peripheral vascular disease
(I70.221 – I70.229, I70.321 – I70.329,
I70.421 – I70.429, I70.521 – I70.529, I70.621 – I70.629, I70.721 – I70.729),
or
d)
Members with
documented metastatic malignant disease, who have a life expectancy of at least
six months, is covered when above criteria are met, (psychological testing would
not be required)
AND the member meets all of the
following criteria:
·
Member experienced
significant pain reduction (50% or more) with a 3- to 7-day trial of
percutaneous spinal stimulation. (A trial of percutaneous spinal
stimulation is considered medically necessary for members who meet the
below-listed criteria, in order to predict whether a dorsal column stimulator
will induce significant pain relief.),
and
·
There is documented
pathology, i.e., an objective basis for the pain complaint,
and
·
Other more conservative
methods of pain management have been tried and failed,
and
·
Member does not have any
untreated existing drug addiction problems (per American Society of Addiction
Medicine (ASAM) guidelines), and
·
Member has obtained
psychiatric clearance, and
·
Member has predominantly
radiating extremity pain.
2.
Revision, replacement or
removal of spinal cord stimulators and their components are covered services.
Replacement components require preauthorization.
3.
Neuromuscular stimulators
are not addressed by this policy; see BI116.
*** “Lack of response to
all other forms of therapy” should include the preferred non-pharmacologic
treatment modalities, the preferred non-opioid pharmacologic interventions and
clinically appropriate procedural interventions described in detail in BI566
(Opioid Therapy for Chronic Pain). G
Trial/failure of opioids is not a requirement for a dorsal column stimulator for
pain.
Codes
Used In This BI:
63650
|
Implant neuroelectrodes
|
63655
|
Implant neuroelectrodes
|
63685
|
Insrt/redo spine n generator
|
63688
|
Revise/remove neuroreceiver
|
A4290
|
Sacral nerve stimulation test lead, each
|
C1767
|
Generator, Neurostimulator (implantable), nonrechargeable
|
C1816
|
Receiver and/or transmitter, Neurostimulator (implantable)
|
C1820
|
Generator, Neurostimulator (implantable), w/rechrgbl battery & charging
system
|
E0745
|
Neuromuscular stimulator, electronic shock unit
|
L8680
|
Implantable neurostim electrode, each
|
L8681
|
Patient program (external) for use w/implantable progrmbl neurostim
pulse genrtr, rplcmnt only
|
L8682
|
Implantable neurostim radiofreq recvr
|
L8683
|
Radiofreq transmit (external) for use w/implantable neurostim radiofreq
recvr
|
L8684
|
Radiofreq transmit (external) for use w/implantable sacral root
neurstmltr recvr for bowel & bladder mgmt, rplcmnt
|
L8685
|
Implantable neurostim pulse generator, single array, rechargeable,
includes extension
|
L8686
|
Implantable neurostim pulse generator, single array, nonrechargeable,
includes extension
|
L8687
|
Implantable neurostim pulse generator, dual array, rechargeable,
includes extension
|
L8688
|
Implantable neurostim pulse generator, dual array, nonrechargeable,
includes extension
|
L8689
|
External recharging system for battery (Internl) for use w/implantable
neurostim, rplcmnt only
|
|
Limits
|
1)
DCS is
considered experimental and investigational for the management of members with
other chronic non-malignant pain (e.g., headache, cephalgia, occipital
neuralgia, intercostal neuralgia, trigeminal neuralgia, phantom limb syndrome,
inguinal pain, and post-herpetic neuralgia), or spasticity because its
effectiveness for these indications has not been established.
2)
Cervical
spinal cord stimulation for the treatment of members with cervical trauma, disc
herniation, or failed cervical spine surgery syndrome, presenting with arm pain,
neck pain, or Cervicogenic headache, is considered experimental and
investigational because its effectiveness for these indications has not been
established.
|
Background
|
Spinal cord
stimulation delivers low voltage electrical stimulation to the dorsal columns of
the spinal cord to block the sensation of pain. Spinal cord stimulation devices
consist of several components:
-
The lead that
delivers the electrical stimulation to the spinal cord;
-
An extension wire that conducts the
electrical stimulation from the power source to the lead, and
-
A power source that
generates the electrical stimulation.
The lead may
incorporate from 4 to 8 electrodes, with 8 electrodes more commonly used for
complex pain patterns, such as bilateral pain or pain extending from the limbs
to the trunk. There are 2 basic types of power source. In one type, the power
source (battery) can be surgically implanted. In another a radiofrequency
receiver is implanted, and the power source is worn externally with an antenna
over the receiver. Totally implantable systems are most commonly used.
There is sufficient
evidence of the effectiveness of dorsal column stimulation in failed back
surgery syndrome and complex regional pain syndrome. North et al (1991b)
reviewed the long-term results of 50 patients with failed back surgery syndrome
who had received implantable DCS. Successful outcome, as judged by at least 50%
sustained analgesia and patient satisfaction with the result, was recorded in
53% of patients at 2.2 years and 47% of patients at 5.0 years. Eighty three
percent of the subjects continued to use their stimulators at the 5-year
follow-up. At the time of follow-up, only 12% of patients were using analgesic
medications with half of them at reduced dosage, compared with 74% before the
commencement of DCS therapy. Moreover, most patients reported an improvement in
ability to perform daily activities. In another report that examined 5-year
follow-up in 102 patients with failed back surgery syndrome undergoing repeated
operation, North et al (1991a) found that most of these patients reported no
change in their abilities to carry out activities of daily living.
Bell et al (1997) as well
as Devulder et al (1997) reported that spinal cord stimulation is cost-effective
in treating patients with chronic failed back surgery syndrome.
Turner, et al. (2004) conducted a systematic review on the effectiveness of DCS
in relieving pain and improving functioning for patients with failed back
surgery syndrome (FBSS) and complex regional pain syndrome (CRPS). These
authors concluded with suggestions for methodologically stronger studies to
provide more definitive data regarding the effectiveness of DCS in relieving
pain and improving functioning, short-term and long-term, among patients with
chronic pain syndromes. Taylor, et al. (2005) assessed the safety and
effectiveness of DCS for the treatment of chronic back and leg pain and FBSS and
concluded that there is moderate evidence for the effectiveness of DSC for these
indications. Furthermore, a recent Cochrane review (Mailis-Gagnon, et al.,
2004) concluded that although there is limited evidence in favor of DCS for FBSS
and CRPS, more research is needed to confirm whether DCS is an effective
treatment for certain types of chronic pain. This is in agreement with the
findings of a recent assessment on spinal cord stimulation for the management of
neuropathic pain by the Ontario Ministry of Health and Long Term Care (2005).
This report stated that FBSS and CRPS are the two most common indications for
DCS. North, et al. (2005) also reported that DCS provided adequate pain relief
in patients with FBSS with predominant low back pain and secondary radicular
pain. Harney, et al. (2005) stated that there is now a significant body of
evidence to support the utilization of DCS in the management of CRPS.
|
Reference
|
1.
Kemler MA, De Vet HC, Barendse GA, et al. (2004) the effect of
spinal cord stimulation in patients with chronic reflex sympathetic dystrophy:
two years` follow-up of the randomized controlled trial. Annals Neurology 2004;
55(1):13-8.
2.
Kemler MA, De Vet HC, Barendse GA, et al. (2004) the effect of
spinal cord stimulation in patients with chronic reflex sympathetic dystrophy:
two years’ follow-up of the randomized controlled trial. Ann Neurol 2004;
55(1):13-8.
3.
Kemler MA, de Vet HC, et al. (2008) Effection of spinal cord
stimulation for chronic complex regional pain syndrome Type I: five-year final
follow-up of patients in a randomized controlled trial. J Neurosurg, 2008;
108:292-8.
4.
Klomp HM, Spincemaille GH, Steyerberg EW, et al.(1999) Spinal cord
stimulation in critical limb ischemia: a randomized trial. Lancet 1999;
353(9158):1040-4.
5.
Lapenna E, Papati D, et al.(2006) Spinal cord stimulation for
patients with refractory angina and previous coronary surgery. Ann Thor Surg,
2006; 82:1704-8.
6.
Mailis-Gagnon A, Furlan AD, Sandoval JA, et al.(2004) Spinal cord
stimulation for chronic pain. The Cochrane Database Systematic Reviews, Issue 3,
Art. No. CD003783.pub2; 2004.
7.
Meyerson BA. (2001) Neurosurgical approaches to pain treatment.
Acta Anaesthesiol Scand 2001; 45:1108-13.
8.
North R, Shipley J, et al.(2007) Practice parameters for the use of
spinal cord stimulation in the treatment of chronic neuropathic pain. Pain Med,
2007; 8:S200-S275.
9.
North RB, Calkins SK, Campbell DS, et al. (2003) Automated,
patient-interactive, spinal cord stimulator adjustment: a randomized controlled
trial. Neurosurgery 2003; 52(3):572-80.
10.
North RB, et
al. (1993) Sperm function assays and their predictive value for fertilization
outcome in IVF therapy: a meta-analysis. Neurosurg 1993; 32:384-395.
11.
North RB, Kidd DH, Lee
MS et al. (1994) a prospective, randomized study of spinal cord stimulation
versus reoperation for failed back surgery syndrome: initial results. Stereotact
Funct Neurosurg 1994; 62(1-4):267-72.
12.
The British Pain
Society. (2005) Spinal cord stimulation for the management of chronic pain.
Recommendations for best clinical practice. http://britishpainsociety.org,
accessed Feb 2007.
13.
Turner JA, Loeser JD,
Bell KG.(1995) Spinal cord stimulation for chronic low back pain: a systematic
literature synthesis. Neurosurgery 1995; 37(6):1088-96.
14.
Ubbink DT, Vermeulen H.
(2003) Spinal cord stimulation for non-reconsdtructable chronic critical leg
ischemia. The Cochrane Database Systematic Reviews 2003, Issue 3, Art NO.
CD004001.
15.
Arkansas
BlueCross BlueShield, Coverage Policy Manual;
Spinal Cord Neurostimulation for
Treatment of Intractable Pain.
Addendum:
Effective
01/01/2017: Removed the
following codes from Codes Used in This BI section: 63661 – 63664, 63688.
Codes no longer referenced in BI.
|
Application to Products
|
This policy applies to all health plans administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet. Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) for those plans insured by QualChoice. In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC, the SPD or EOC, as applicable, will prevail. State and federal mandates will be followed as they apply.
|
Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.
|
|